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OBJECTIVE — To investigate the relationships of serum adipocyte fatty acid–binding pro-
tein (A-FABP) and epidermal fatty acid–binding protein (E-FABP) with renal dysfunction and
macrovascular complications in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — The associations of serum A-FABP and E-
FABP with markers of renal function, nephropathy staging, and macrovascular complications
were examined in 237 type 2 diabetic patients.
RESULTS — SerumA-FABPandE-FABPcorrelatedsigniﬁcantlywithserumcreatinine,mean
albumin excretion rate, and glomerular ﬁltration rate (all P  0.001) and were independently
associatedwithdiabeticnephropathystaging(P0.001andP0.05,respectively).Circulating
levels of both types of FABP were increased (P  0.01) in subjects with macrovascular compli-
cations. Serum A-FABP was independently associated with macrovascular complications (odds
ratio 2.92 [95% CI 1.42–6.01]; P  0.004).
CONCLUSIONS — Serum A-FABP and E-FABP might be novel serum biomarkers for eval-
uating the progression of nephropathy and its cardiovascular risk in type 2 diabetic patients.
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A
dipocytefattyacid–bindingprotein
(A-FABP)andepidermalfattyacid–
binding protein (E-FABP), highly
expressed in adipocytes and macro-
phages, have been shown to mediate obe-
sity-related metabolic disorders and
atherosclerosis in animal studies (1). We
have recently demonstrated that both
types of FABP circulate in the human
bloodstream (2,3), with levels closely as-
sociated with parameters of adiposity, in-
sulin resistance, the metabolic syndrome,
and carotid atherosclerosis (2–4). This
study examined the relationships of cir-
culating A-FABP and E-FABP with dia-
betic nephropathy and its associated
macrovascular complications in 237 type
2 diabetic patients in various stages of
nephropathy.
RESEARCH DESIGN AND
METHODS— This cohort included
237 Chinese type 2 diabetic patients
(mean  SD age 55.8  14.2 years, BMI
25.5  4.3 kg/m
2, 110 male and 127 fe-
male) from the Diabetes Clinic, Queen
Mary Hospital (Hong Kong, China), with
complete sets of renal function assess-
ment data collected as part of two previ-
ouslypublishedstudies(3,5).Noneofthe
patients were on thiazolidinediones. In-
formed consent was obtained, and the
protocol was approved by the local ethics
committee.
Allsubjectswereassessedafteratleast
10 h of overnight fasting. Details on the
assessment for hypertension, various an-
thropometric and biochemical parame-
ters, serum high-sensitivity C-reactive
protein, A-FABP (intra-assay coefﬁcients
of variation [CVs] 3.9–6.6% and interas-
say CVs 2.6–5.1%) and E-FABP (intra-
assay CVs 4.5–4.9% and interassay CVs
5.7–5.9%) (BioVendor Laboratory Medi-
cine, Modr ˇice, Czech Republic) were re-
ported previously (2–6). Serum soluble
tumor necrosis factor receptor II (sTNF
RII) was measured with ELISA kits from
R&D Systems (Minneapolis, MN).
Mean albumin excretion rate (MAER)
was estimated from the albumin content
of two consecutive 12-h overnight urine
samples, which were assayed nephelo-
metrically.Subjectswereclassiﬁedasnor-
moalbuminuric (MAER 20 g/min),
microalbuminuric (MAER 20–200 g/
min),ormacroalbuminuric(MAER200
g/min) (6). Glomerular ﬁltration rate
(GFR) was estimated using the formula
from the Modiﬁcation of Diet in Renal
Disease (MDRD) study (7). Macrovascu-
larcomplicationsincludedischemicheart
disease,stroke,orperipheralvasculardis-
ease, diagnosed clinically and docu-
mented on electrocardiogram, myocardial
perfusion scan, or coronary angiogram;
computed tomography brain scan; or
Doppler studies, respectively.
All analyses were performed with
SPSS (version 15; SPSS, Chicago, IL).
Skewed data were logarithmically trans-
formed.One-wayANOVAora
2testwas
used for comparisons between groups,
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adjusted using partial correlation. Multi-
pletestingwascorrectedusingBonferroni
correction. Multinomial and binary logis-
ticregressionswereusedtodeterminethe
variables with independent signiﬁcant as-
sociations with nephropathy staging and
macrovascular complications, respec-
tively. P 0.05 was considered statisti-
cally signiﬁcant.
RESULTS— There were signiﬁcant
and progressive increases in serum A-
FABP and E-FABP across the three stages
of diabetic nephropathy (for both, with
adjustment for trend, P  0.001) (Table
A1 in the online appendix, available at
http://dx.doi.org/10.2337/dc08-1333). Se-
rumA-FABPcorrelatedpositivelywithse-
rum creatinine and MAER and negatively
withMDRD-GFR(allP0.001,adjusted
for sex, age, and waist circumference)
(Fig. 1A–C). Age- and waist circumfer-
ence–adjusted serum E-FABP also corre-
latedpositivelywithserumcreatinineand
MAER and negatively with MDRD-GFR
(all P  0.001) (Fig. 1D–F). The correla-
tions of serum A-FABP or E-FABP with
serum creatinine and MDRD-GFR re-
mainedsigniﬁcantevenafteradjustingfor
LDL cholesterol, hypertension, and sTNF
RII (adjusted P  0.015 to 0.001).
There was no signiﬁcant correlation of
FABP with either A1C or statin use. Se-
rum E-FABP, but not A-FABP, correlated
with adiponectin (r  0.213; P 
0.001).
Multinomial regressions, including
factorswithbiologicalrelevanceorsignif-
icant associations (corrected P  0.05)
with nephropathy staging, showed that
serum A-FABP was independently associ-
ated with nephropathy staging for micro-
albuminuria versus normoalbuminuria
(odds ratio [OR] 3.04 [95% CI 1.61–
5.74];P0.001)andformacroalbumin-
uria versus normoalbuminuria (4.14
[1.83–9.33]; P  0.001) together with
LDL cholesterol (2.15 [1.23–3.77]; P 
0.007) (online appendix Table A2). Se-
rum sTNF RII, A-FABP, and E-FABP
were input one at a time because of their
strong correlations (r  0.4; P  0.001).
Repeated analysis yielded similar results
for serum E-FABP (OR 1.83, P  0.035
for microalbuminuria vs. normoalbu-
minuria, and OR 4.93, P  0.001 for
macroalbuminuria vs. normoalbuminuria).
Thirty-six micro- or macroalbumin-
uric subjects had macrovascular compli-
cations. They had higher serum A-FABP
and E-FABP (both P  0.01) than sub-
jects with no macrovascular complica-
tions (online appendix Table A3). Binary
logistic regression, which included pa-
rameters having signiﬁcant associations
or possible biological relevance with ma-
crovascular complications, revealed that
serum A-FABP (OR 2.92 [95% CI 1.42–
6.01]; P  0.004) and fasting glucose
(1.15 [1.00–1.33]; P  0.046) were in-
dependentlyassociatedwithmacrovascu-
lar complications (online appendix Table
A4). Serum A-FABP, E-FABP, sTNF RII,
andMDRD-GFR,beinghighlycorrelated,
were analyzed one at a time. MDRD-GFR,
but not serum E-FABP or sTNF RII, was
signiﬁcantly associated with macrovascu-
lar complications (OR 0.24; P  0.006).
CONCLUSIONS — This study pro-
vides novel evidence that serum A-FABP
and E-FABP in type 2 diabetic patients
were independently associated with ne-
phropathy staging and correlated posi-
tively with serum creatinine and
negatively with MDRD-GFR, even after
adjustment for age, adiposity, LDL cho-
lesterol, hypertension, and sTNF RII. The
elevated levels of these FABPs might have
Figure 1—Correlations between serum levels of the two FABPs and indexes of renal function.
Serum A-FABP levels correlated signiﬁcantly with serum creatinine (A), MAER (B), and MDRD-
GFR(C).SerumE-FABPalsocorrelatedsigniﬁcantlywithserumcreatinine(D),MAER(E),and
MDRD-GFR (F). Ln, natural logarithm.
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ance and increased production by acti-
vated macrophages in diabetic
nephropathy. Macrophage accumulation
in the kidney, which increases with the
progression of nephropathy in diabetes
andrenalinjury(8),istheprimarysource
of inﬂammation under this pathological
condition. Both FABPs are highly ex-
pressed in macrophages (1), and several
proinﬂammatory stimuli could induce A-
FABP expressions in macrophages (9,
10). On the other hand, both FABPs
have been implicated as key mediators
of inﬂammation (1). Taken together,
macrophage accumulation in the kid-
ney and the augmented expressions of
these FABPs in macrophages would ag-
gravate local inﬂammation and contrib-
ute to the progression of nephropathy
in diabetes.
We have also demonstrated the sig-
niﬁcant increases of serum A-FABP and
E-FABP in macrovascular complications
and the independent association between
serum A-FABP and macrovascular com-
plications. These new ﬁndings would
support a causative role of these FABPs in
the pathogenesis of cardiovascular dis-
eases,suggestedbypreviousanimal,ge-
netic, and epidemiological studies
(1,3,4,11). In summary, our ﬁndings
raise the possibility that A-FABP and E-
FABP may be used as serum biomarkers
for stratifying nephropathy staging and
cardiovascular risks in diabetic patients.
Acknowledgments— A.X. was supported by
grant KKU 2/07C from the Collaborative Re-
search Fund. K.L. was supported by grants
HKU7637/05Mand7590/06MfromtheHong
Kong Research Grants Council.
No potential conﬂicts of interest relevant to
this article were reported.
References
1. FuruhashiM,HotamisligilGS:Fattyacid-
binding proteins: role in metabolic dis-
eases and potential as drug targets. Nat
Rev Drug Discov 7:489–503, 2008
2. Xu A, Wang Y, Xu JY, Stejskal D, Tam S,
Zhang JL, Wat NM, Wong WK, Lam KS:
Adipocyte fatty acid-binding protein is a
plasma biomarker closely associated with
obesity and metabolic syndrome. Clin
Chem 52:405–413, 2006
3. Yeung DC, Wang Y, Xu A, Cheung SC,
Wat NM, Fong DY, Fong CH, Chau MT,
Sham PC, Lam KS: Epidermal fatty-acid-
binding protein: a new circulating bi-
omarkerassociatedwithcardio-metabolic
risk factors and carotid atherosclerosis.
Eur Heart J. 4 July 2008 [Epub ahead of
print]
4. Yeung DC, Xu A, Cheung CW, Wat NM,
Yau MH, Fong CH, Chau MT, Lam KS:
Serum adipocyte fatty acid-binding pro-
tein levels were independently associated
with carotid atherosclerosis. Arterioscler
Thromb Vasc Biol 27:1796–1802, 2007
5. Hoo RL, Chow WS, Yau MH, Xu A, Tso
AW,TseHF,FongCH,TamS,ChanL,Lam
KS: Adiponectin mediates the suppressive
effect of rosiglitazone on plasminogen acti-
vator inhibitor-1 production. Arterioscler
Thromb Vasc Biol 27:2777–2782, 2007
6. Liu YF, Wat NM, Chung SS, Ko BC, Lam
KS: Diabetic nephropathy is associated
with the 5-end dinucleotide repeat poly-
morphism of the aldose reductase gene in
Chinese subjects with type 2 diabetes.
Diabet Med 19:113–118, 2002
7. Levey AS, Bosch JP, Lewis JB, Greene T,
Rogers N, Roth D, the Modiﬁcation of
Diet in Renal Disease Study Group: A
more accurate method to estimate glo-
merular ﬁltration rate from serum creati-
nine: a new prediction equation. Ann
Intern Med 140:461–470, 1999
8. Chow FY, Nikolic-Paterson DJ, Ozols E,
Atkins RC, Tesch GH: Intercellular adhe-
sion molecule-1 deﬁciency is protective
against nephropathy in type 2 diabetic
db/db mice. J Am Soc Nephrol 16:1711–
1722, 2005
9. Kazemi MR, McDonald CM, Shigenaga
JK, Grunfeld C, Feingold KR: Adipocyte
fatty acid-binding protein expression and
lipid accumulation are increased during
activationofmurinemacrophagesbytoll-
like receptor agonists. Arterioscler Thromb
Vasc Biol 25:1220–1224, 2005
10. Fu Y, Luo N, Lopes-Virella MF: Oxi-
dized LDL induces the expression of
ALBP/aP2 mRNA and protein in human
THP-1 macrophages. J Lipid Res 41:
2017–2023, 2000
11. Tuncman G, Erbay E, Hom X, De Vivo I,
Campos H, Rimm EB, Hotamisligil GS: A
genetic variant at the fatty acid-binding
protein aP2 locus reduces the risk for hy-
pertriglyceridemia, type 2 diabetes, and
cardiovascular disease. Proc Natl Acad Sci
USA103:6970–6975, 2006
Fatty acid–binding proteins and nephropathy
134 DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009